Continuous intrathecal infusion of ziconotide for treatment of chronic malignant and nonmalignant pain over 12 months: A prospective, open-label study

Neuromodulation

Volumn 11, Issue 1, 2008, Pages 40-49

  Ellis, David J ^b,c   Dissanayake, Sanjeeva ^b,d   McGuire, Dawn ^b,e   Charapata, Steven G ^f   Staats, Peter S ^g   Wallace, Mark S ^a   Grove, Gene W ^h   Vercruysse, Piet ⁱ  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ELAN PHARMACEUTICALS   (United States)

^c ARYx Therapeutics   (United States)

^d MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

^e CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^f Pain Management Associates   (United States)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h Orthopedic Sports Medicine Center   (United States)

ⁱ Multidisciplinary Pain Unit   (Belgium)

Author keywords

Chronic malignant pain; Chronic nonmalignant pain; Intrathecal; Ziconotide

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CORTICOSTEROID; HYPNOTIC SEDATIVE AGENT; LOCAL ANESTHETIC AGENT; MORPHINE; MUSCLE RELAXANT AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OMEGA CONOTOXIN MVIIA; OPIATE DERIVATIVE; PLACEBO;

ABNORMAL VISION; ADULT; AGED; AGITATION; AMBLYOPIA; ANOREXIA; ANXIETY DISORDER; ARTICLE; ASTHENIA; ATAXIA; BLURRED VISION; CANCER PAIN; CHILL; CHRONIC PAIN; CLINICAL TRIAL; CONFUSION; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSESTHESIA; FEMALE; GAIT; HALLUCINATION; HUMAN; HYPESTHESIA; HYPOTENSION; LABORATORY TEST; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MENTAL FUNCTION; MONOTHERAPY; MULTICENTER STUDY; MUSCLE HYPERTONIA; MYASTHENIA; NAUSEA; NAUSEA AND VOMITING; NERVOUSNESS; NYSTAGMUS; ORTHOSTATIC HYPOTENSION; PAIN; PAIN ASSESSMENT; PROSPECTIVE STUDY; REFLEX; RISK BENEFIT ANALYSIS; SIDE EFFECT; SOMNOLENCE; SPEECH DISORDER; TASTE DISORDER; TREATMENT RESPONSE; TREMOR; URINE RETENTION; VERBAL BEHAVIOR; VISUAL ANALOG SCALE; VITAL SIGN; VOMITING; XEROSTOMIA;

EID: 37549018110     PISSN: 10947159     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1525-1403.2007.00141.x     Document Type: Article

References (40)

1. Hassenbusch SJ, Portenoy RK. Current practices in intraspinal therapy: a survey of clinical trends and decision making. J Pain Symptom Manage 2000 20 : S4 S11.
2. Hassenbusch SJ, Portenoy RK, Cousins M et al. Polyanalgesic Consensus Conference 2003: an update on the management of pain by intraspinal drug delivery - report of an expert panel. J Pain Symptom Manage 2004 27 : 540 563.
3. Arner S, Arner B. Differential effects of epidural morphine in the treatment of cancer-related pain. Acta Anaesthesiol Scand 1985 29 : 32 36.
4. Erdine S, Aldemir T. Long-term results of peridural morphine in 225 patients. Pain 1991 45 : 155 159.
5. Hanks GW, Forbes K. Opioid responsiveness. Acta Anaesthesiol Scand 1997 41 : 154 158.
6. Hogan Q, Haddox JD, Abram S, Weissman D, Taylor ML, Janjan N. Epidural opiates and local anesthetics for the management of cancer pain. Pain 1991 46 : 271 279.
7. Paice JA, Penn RD, Shott S. Intraspinal morphine for chronic pain: a retrospective, multicenter study. J Pain Symptom Manage 1996 11 : 71 80.
8. Portenoy RK. Chronic opioid therapy in nonmalignant pain. J Pain Symptom Manage 1990 5 : S46 S62.
9. Samuelsson H, Malmberg F, Eriksson M, Hedner T. Outcomes of epidural morphine treatment in cancer pain: nine years of clinical experience. J Pain Symptom Manage 1995 10 : 105 112.
10. Samuelsson H, Nordberg G, Hedner T, Lindqvist J. CSF and plasma morphine concentrations in cancer patients during chronic epidural morphine therapy and its relation to pain relief. Pain 1987 30 : 303 310.
11. Abs R, Verhelst J, Maeyaert J et al. Endocrine consequences of long-term intrathecal administration of opioids. J Clin Endocrinol Metab 2000 85 : 2215 2222.
12. Finch PM, Roberts LJ, Price L, Hadlow NC, Pullan PT. Hypogonadism in patients treated with intrathecal morphine. Clin J Pain 2000 16 : 251 254.
13. Anderson VC, Burchiel KJ. A prospective study of long-term intrathecal morphine in the management of chronic nonmalignant pain. Neurosurgery 1999 44 : 289 300.
14. Krames ES, Lanning RM. Intrathecal infusional analgesia for nonmalignant pain: analgesic efficacy of intrathecal opioid with or without bupivacaine. J Pain Symptom Manage 1993 8 : 539 548.
15. De Conno F, Caraceni A, Martini C, Spoldi E, Salvetti M, Ventafridda V. Hyperalgesia and myoclonus with intrathecal infusion of high-dose morphine. Pain 1991 47 : 337 339.
16. Devulder J. Hyperalgesia induced by high-dose intrathecal sufentanil in neuropathic pain. J Neurosurg Anesthesiol 1997 9 : 146 148.
17. Coffey RJ, Burchiel K. Inflammatory mass lesions associated with intrathecal drug infusion catheters: report and observations on 41 patients. Neurosurgery 2002 50 : 78 86.
18. Yaksh TL, Hassenbusch S, Burchiel K, Hildebrand KR, Page LM, Coffey RJ. Inflammatory masses associated with intrathecal drug infusion: a review of preclinical evidence and human data. Pain Med 2002 3 : 300 312.
19. PRIALT. Package Insert. San Diego, CA : Elan Pharmaceuticals Inc., 2005.
20. PRIALT. Summary of Product Characteristics. Shannon, County Clare, Ireland : Elan Pharma International Ltd., 2005.
21. McGivern JG, McDonough SI. Voltage-gated calcium channels as targets for the treatment of chronic pain. Curr Drug Targets CNS Neurol Disord 2004 3 : 457 478.
22. Miljanich GP. Ziconotide: neuronal calcium channel blocker for treating severe chronic pain. Curr Med Chem 2004 11 : 3029 3040.
23. Staats PS, Yearwood T, Charapata SG et al. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial. JAMA 2004 291 : 63 70.
24. Wallace MS, Charapata SG, Fisher R et al. Intrathecal ziconotide in the treatment of chronic nonmalignant pain: a randomized, double-blind, placebo-controlled clinical trial. Neuromodulation 2006 9 : 75 86.
25. Pollard CA. Preliminary validity study of the Pain Disability Index. Percept Mot Skills 1984 59 : 974.
26. Tait RC, Chibnall JT, Krause S. The Pain Disability Index: psychometric properties. Pain 1990 40 : 171 182.
27. Tait RC, Pollard CA, Margolis RB, Duckro PN, Krause SJ. The Pain Disability Index: psychometric and validity data. Arch Phys Med Rehabil 1987 68 : 438 441.
28. Gilson BS, Gilson JS, Bergner M et al. The Sickness Impact Profile. Development of an outcome measure of health care. Am J Public Health 1975 65 : 1304 1310.
29. Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In : MacLeod CM, ed. Evaluation of chemotherapeutic agents. New York : Columbia University Press, 1949 : 191 205.
30. Schag CC, Heinrich RL, Ganz PA. Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol 1984 2 : 187 193.
31. Wermeling D, Drass M, Ellis D et al. Pharmacokinetics and pharmacodynamics of intrathecal ziconotide in chronic pain patients. J Clin Pharmacol 2003 43 : 624 636.
32. Fisher R, Hassenbusch S, Krames E et al. A consensus statement regarding the present suggested titration for Prialt (ziconotide). Neuromodulation 2005 8 : 153 154.
33. Rauck RL, Wallace MS, Leong MS et al. A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain. J Pain Symptom Manage 2006 31 : 393 406.
34. Wang YX, Gao D, Pettus M, Phillips C, Bowersox SS. Interactions of intrathecally administered ziconotide, a selective blocker of neuronal N-type voltage-sensitive calcium channels, with morphine on nociception in rats. Pain 2000 84 : 271 281.
35. Basbaum AI. Insights into the development of opioid tolerance. Pain 1995 61 : 349 352.
36. Collin E, Cesselin F. Neurobiological mechanisms of opioid tolerance and dependence. Clin Neuropharmacol 1991 14 : 465 488.
37. Kennedy C, Henderson G. Mu-opioid receptor inhibition of calcium current: development of homologous tolerance in single SH-SY5Y cells after chronic exposure to morphine in vitro. Mol Pharmacol 1991 40 : 1000 1005.
38. Kristipati R, Nadasdi L, Tarczy-Hornoch K et al. Characterization of the binding of omega-conopeptides to different classes of non-L-type neuronal calcium channels. Mol Cell Neurosci 1994 5 : 219 228.
39. McGuire D, Bowersox S, Fellmann JD, Luther RR. Sympatholysis after neuron-specific, N-type, voltage-sensitive calcium channel blockade: first demonstration of N-channel function in humans. J Cardiovasc Pharmacol 1997 30 : 400 403.
40. Ellis D, Ludington E, Miljanich G, Chandler S, Kartzinel R. Analysis of creatine kinase (CK) levels during intrathecal (IT) ziconotide (Z) treatment of patients with severe chronic pain. Sydney, Australia : Poster presented at International Association for the Study of Pain 11th World Congress on Pain, August 21-26, 2005.